-+ 0.00%
-+ 0.00%
-+ 0.00%

ENHERTU® RECOMMENDED FOR APPROVAL IN THE EU BY CHMP AS ADJUVANT TREATMENT FOR PATIENTS WITH RESIDUAL DISEASE AFTER NEOADJUVANT TREATMENT FOR HER2 POSITIVE EARLY BREAST CANCER

路透·09/18/2026 12:00:00

登录查看新闻详情